TLR3 and neoplasm: Hiltonol® (Oncovir, Inc., Washington, DC, USA), or polyinosinic–polycytidilic acid (poly-ICLC), is a Toll-like receptor-3 (TLR3) agonist that has been extensively studied as a cancer immune adjuvant using a variety of tumor vaccination strategies [9,10,11] but has not previously been combined with oregovomab or other indirect immunizing antibodies.